The FDA accepted the new drug application for iberdomide based on minimal residual disease negativity benefit shown in the ...
The browser you are using is no longer supported on this site. It is highly recommended that you use the latest versions of a supported browser in order to receive an optimal viewing experience. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results